CRYOPORT, INC. Increase (Decrease) in Deferred Liabilities
CRYOPORT, INC. (CYRX) reported Increase (Decrease) in Deferred Liabilities of -$551.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2024-05-08
- CRYOPORT, INC. increase (decrease) in deferred liabilities for the quarter ending 2024-03-31 was -$551.00K, a 323.98% decline year-over-year.
- CRYOPORT, INC. increase (decrease) in deferred liabilities for the quarter ending 2023-09-30 was $30.00K.
- CRYOPORT, INC. increase (decrease) in deferred liabilities for the quarter ending 2023-06-30 was -$466.00K.
- CRYOPORT, INC. increase (decrease) in deferred liabilities for the quarter ending 2023-03-31 was $246.00K.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month |
|---|---|---|---|
| 2024-03-31 | -$551.00K 10-Q · filed 2024-05-08 | ||
| 2023-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$436.00K derived: sum of 2 quarters · filed 2023-11-09 | -$190.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$466.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$220.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $246.00K 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | -$488.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$969.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$481.00K 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |